Retrospective study of weekly paclitaxel-cetuximab (WPC) in unselected patients (p) with recurrent/metastatic head and neck squamous cell carcinoma (RM-SCCHN)

被引：0
|
作者：
Pajares Bernad, I. [1 ]
Martinez Trufero, J. [1 ]
Calera Urquizu, L. [1 ]
Cebolleo de Miguel, A. [1 ]
Pazo Cid, R. [1 ]
Lanzuela Valero, M. [2 ]
Agsustin, M. J. [3 ]
Millastre, E. [1 ]
Santander Lobera, C. [1 ]
Alvarez Alejandro, M. [1 ]
Gimeno, N. [4 ]
Malo Yague, M. [5 ]
Llorente, Y. [6 ]
Anton Torres, A. [1 ]
机构：
[1] Hosp Miguel Servet, Dept Med Oncol, Zaragoza, Spain
[2] Hosp Miguel Servet, Dept Radiotherapy, Zaragoza, Spain
[3] Hosp Miguel Servet, Dept Pharm, Zaragoza, Spain
[4] Hosp Royo Villanova, Dept Med Oncol, Zaragoza, Spain
[5] Hosp Ernest Lluch, Dept Hematol, Calatayud, Spain
[6] Arrabal Ctr, Support Care, Zaragoza, Spain
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw376.43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
991P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors
    Pajares Bernad, I.
    Martinez Trufero, J.
    Calera Urquizu, L.
    Pazo Cid, R. A.
    Cebollero de Miguel, A.
    Agustin, M. J.
    Lanzuela, M.
    Anton, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (06): : 769 - 776
  • [2] Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Fushimi, Chihiro
    Baba, Daisuke
    Masubuchi, Tatsuo
    Yamazaki, Morio
    Kitani, Yosuke
    Kitajima, Tatsuya
    Tanaka, Junpei
    Hanyu, Kenji
    Tanaka, Naruhisa
    Miura, Kouki
    Tada, Yuichiro
    IN VIVO, 2020, 34 (05): : 2653 - 2657
  • [3] Activity of weekly paclitaxel−cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors
    I. Pajares Bernad
    J. Martínez Trufero
    L. Calera Urquizu
    R. A. Pazo Cid
    A. Cebollero de Miguel
    M. J. Agustin
    M. Lanzuela
    A. Antón
    Clinical and Translational Oncology, 2017, 19 : 769 - 776
  • [4] Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
    Hitt, R.
    Irigoyen, A.
    Nunez, J.
    Grau, J.
    Garcia Saenz, J.
    Pastor, M.
    Jara, C.
    Garcia Giron, C.
    Hidalgo, M.
    Cruz Hernandez, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Weekly cetuximab and paclitaxel combination in metastatic/recurrent squamous cell cancer carcinoma of the head and neck (SCCHN): Clinical experience of a single institution
    Diaz de Corcuera, I.
    Serrano, C.
    Perez, J.
    Quispe, I.
    Arguis, M.
    Munoz, E.
    Benavente, S.
    Martinez, P.
    Parera, M.
    del Campo, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Takeshita, Naohiro
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Wada, Akihisa
    Sato, Masanobu
    Tanaka, Hideki
    Tanaka, Nobukazu
    Onaga, Ryutaro
    Hoshi, Yuta
    Sakashita, Shingo
    Ishii, Genichiro
    Tahara, Makoto
    ORAL ONCOLOGY, 2023, 147
  • [7] A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
    Nakano, Kenji
    Marshall, Shoko
    Taira, Shinichiro
    Sato, Yukiko
    Tomomatsu, Junichi
    Sasaki, Toru
    Shimbashi, Wataru
    Fukushima, Hirofumi
    Yonekawa, Hiroyuki
    Mitani, Hiroki
    Kawabata, Kazuyoshi
    Takahashi, Shunji
    ORAL ONCOLOGY, 2017, 73 : 21 - 26
  • [8] Retrospective analysis of the use of cetuximab (CTX) and paclitaxel (PTX) combination in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Soria Rivas, Ainara
    Rodriguez Garrote, Mercedes
    Olmedo Garcia, Maria Eugenia
    Lopez, Maria
    Garrido Lopez, Pilar
    Carrato, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Clinical experience with Cetuximab and Paclitaxel combination in metastatic/recurrent squamous cell cancer carcinoma of the head and neck (SCCHN) - retrospective analysis of a single institution
    Diaz de Corcuera, I.
    Serrano, C.
    Perez, J.
    Quispe, I.
    Arguis, M.
    Munoz, E.
    Benavente, S.
    Martinez, P.
    Parera, M.
    del Campo, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 485 - 485
  • [10] Development of a predictive radiomics signature for response to immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN)
    Prawira, A.
    Dufort, P.
    Halankar, J.
    Paravasthu, D. M.
    Hansen, A.
    Spreafico, A.
    Razak, A. R. Abdul
    Chen, E.
    Jang, R. W.
    Metser, U.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2016, 27
12345